Literature DB >> 34933094

Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy.

Rebecca Bornstein1, Katerina James2, Julia Stokes2, Kyung Yeon Park2, Ernst-Bernhard Kayser2, John Snell2, Angela Bard2, Yihan Chen2, Franck Kalume3, Simon C Johnson4.   

Abstract

Genetic mitochondrial diseases are the most frequent cause of inherited metabolic disorders and one of the most prevalent causes of heritable neurological disease. Leigh syndrome is the most common clinical presentation of pediatric mitochondrial disease, typically appearing in the first few years of life, and involving severe multisystem pathologies. Clinical care for Leigh syndrome patients is difficult, complicated by the wide range of symptoms including characteristic progressive CNS lesion, metabolic sequelae, and epileptic seizures, which can be intractable to standard management. While no proven therapies yet exist for the underlying mitochondrial disease, a ketogenic diet has led to some reports of success in managing mitochondrial epilepsies, with ketosis reducing seizure risk and severity. The impact of ketosis on other aspects of disease progression in Leigh syndrome has not been studied, however, and a rigorous study of the impact of ketosis on seizures in mitochondrial disease is lacking. Conversely, preclinical efforts have identified the intracellular nutrient signaling regulator mTOR as a promising therapeutic target, with data suggesting the benefits are mediated by metabolic changes. mTOR inhibition alleviates epilepsies arising from defects in TSC, an mTOR regulator, but the therapeutic potential of mTOR inhibition in seizures related to primary mitochondrial dysfunction is unknown. Given that ketogenic diet is used clinically in the setting of mitochondrial disease, and mTOR inhibition is in clinical trials for intractable pediatric epilepsies of diverse causal origins, a direct experimental assessment of their effects is imperative. Here, we define the impact of dietary ketosis on survival and CNS disease in the Ndufs4(KO) mouse model of Leigh syndrome and the therapeutic potential of both dietary ketosis and mTOR inhibition on seizures in this model. These data provide timely insight into two important clinical interventions.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epilepsy; Ketogenic diet; Ketosis; Mitochondrial disease; Seizure; mTOR

Mesh:

Substances:

Year:  2021        PMID: 34933094      PMCID: PMC8770160          DOI: 10.1016/j.nbd.2021.105594

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   7.046


  45 in total

Review 1.  The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies.

Authors:  M A Tarnopolsky
Journal:  Adv Drug Deliv Rev       Date:  2008-07-04       Impact factor: 15.470

Review 2.  mTOR inhibitors as a new therapeutic option for epilepsy.

Authors:  Paolo Curatolo; Romina Moavero
Journal:  Expert Rev Neurother       Date:  2013-06       Impact factor: 4.618

Review 3.  Ketogenic diet and childhood neurological disorders other than epilepsy: an overview.

Authors:  Alberto Verrotti; Giulia Iapadre; Simone Pisano; Giangennaro Coppola
Journal:  Expert Rev Neurother       Date:  2016-11-21       Impact factor: 4.618

Review 4.  Epilepsy in mitochondrial disorders.

Authors:  Josef Finsterer; Sinda Zarrouk Mahjoub
Journal:  Seizure       Date:  2012-03-27       Impact factor: 3.184

Review 5.  Mitochondrial disorders and epilepsy.

Authors:  I Desguerre; M Hully; M Rio; R Nabbout
Journal:  Rev Neurol (Paris)       Date:  2014-05-05       Impact factor: 2.607

6.  mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.

Authors:  Simon C Johnson; Melana E Yanos; Ernst-Bernhard Kayser; Albert Quintana; Maya Sangesland; Anthony Castanza; Lauren Uhde; Jessica Hui; Valerie Z Wall; Arni Gagnidze; Kelly Oh; Brian M Wasko; Fresnida J Ramos; Richard D Palmiter; Peter S Rabinovitch; Philip G Morgan; Margaret M Sedensky; Matt Kaeberlein
Journal:  Science       Date:  2013-11-14       Impact factor: 47.728

7.  Current progress in the therapeutic options for mitochondrial disorders.

Authors:  E Koňaříková; A Marković; Z Korandová; J Houštěk; T Mráček
Journal:  Physiol Res       Date:  2020-11-02       Impact factor: 1.881

Review 8.  The genetics of Leigh syndrome and its implications for clinical practice and risk management.

Authors:  Ilene S Ruhoy; Russell P Saneto
Journal:  Appl Clin Genet       Date:  2014-11-13

Review 9.  Molecular basis of Leigh syndrome: a current look.

Authors:  Manuela Schubert Baldo; Laura Vilarinho
Journal:  Orphanet J Rare Dis       Date:  2020-01-29       Impact factor: 4.123

Review 10.  Emerging concepts in the therapy of mitochondrial disease.

Authors:  Carlo Viscomi; Emanuela Bottani; Massimo Zeviani
Journal:  Biochim Biophys Acta       Date:  2015-03-10
View more
  1 in total

1.  Leukocytes mediate disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndrome.

Authors:  Julia C Stokes; Rebecca L Bornstein; Katerina James; Kyung Yeon Park; Kira A Spencer; Katie Vo; John C Snell; Brittany M Johnson; Philip G Morgan; Margaret M Sedensky; Nathan A Baertsch; Simon C Johnson
Journal:  JCI Insight       Date:  2022-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.